Showing posts with label Pfizer. Show all posts
Showing posts with label Pfizer. Show all posts

Tuesday, January 08, 2013

It’s time to unleash the power of social technologies

In today’s competitive environment, firms can boost productivity and enhance performance by leveraging social technologies to support business needs

Social technologies have radically transformed the world of business. They have enabled globe-spanning supply lines, real-time information exchange, and allowed businesses to enhance their performance. These powerful technologies challenge existing management practices and models, consequently many executives are rethinking their infrastructure for collaboration and communication.

Typically these technologies include blogs, wikis, podcasts, information tagging, widgets, mashups, prediction markets and social networks. The use of these social technologies within companies is referred to as Enterprise 2.0. Global enterprise spending on these technologies is predicted to increase dramatically to $4.6 billion by the end of 2013, with a 43% year-on-year growth, which makes it the fastest growing technology in the enterprise software industry.

Despite the recession, a growing number of innovative firms are integrating social technologies into their businesses, including General Electric (GE), Proctor & Gamble (P&G), Shell, KPMG and Airbus. These forward-thinking firms are adapting their traditional management practices while leveraging Enterprise 2.0 technologies. However, when it comes to the current management practices that dominate in the majority of companies – a large number of leaders are still ‘unsure about the relevance’ of social technologies to allocate their resources and capabilities effectively. The big question is ‘can these social technologies actually boost business performance?’

Our research has found that companies can boost productivity and enhance performance by leveraging social technologies to support business needs. A number of companies have implemented Enterprise 2.0 applications for a variety of purposes such as research & development, marketing, customer service and knowledge management. Global service firms such as Accenture, Pfizer, BT and IBM have used these technologies to rapidly identify who within their organisation know ‘what’ and thus consequently share their expertise quickly. In fact, in some cases this goes beyond the UK borders to creating global outreach platforms for collaboration and communication.


Source : IIPM Editorial, 2012.
An Initiative of IIPM, Malay Chaudhuri
For More IIPM Info, Visit below mentioned IIPM articles.
Posted by at
Labels: , , , , , , , , , , , , , ,

Thursday, December 06, 2012

Wyzer or Pfyeth? (Whatever...)

Pfizer’s bid for Wyeth makes sense; but it suffers from the fundamental problem with M&As – high risk!

Abuyout offer? Nothing new about it... Recession? Again, not a new occurence... Now, combine the two and there you have your eyes opened, and wide! And here’s Pfizer proving why both can coexist, through its $68 billion bid for Wyeth. In the name of cost synergies, Pfizer hopes to save $4 billion annually in operational costs via streamlining of activities. But as researches over time have proven, most big-ticket M&As have failed to generate any synergy! So here’s the question – is the deal logical?

Pfizer faces a major challenge of new drug development as its patent for Lipitor (that contributed to $6 billion in FY2008) will expire in November 2011. And that gives a ‘real’ reason for the merger – revenue generation! Wyeth’s core competence is in R&D. About 350 scientists in its labs are solely working on the much-awaited drug formulae for treating Alzheimer’s disease that can become the next drug wonder for Pfizer (generating revenues up to $20 billion annually). Currently, every major drug company is working on a drug to treat Alzheimer’s, and Wyeth having already invested more than $1 billion in the same, naturally gives Pfizer an automatic lead. Then there are other drugs that would fall into Pfizer’s basket through the deal, like Enbrel (an arthritis drug) that earned $3.8 billion in revenues for Wyeth during 2008, Prevnar (pediatric vaccine) that generated $3 billion in 2008, Xyntha (a hemophilia treating drug) that could help garner $1 billion in 2009. Naturally, it is revenues that entices Pfizer more! Commenting on the deal, David Lugg, Credit Analyst, S&P, quotes, “The company will reap the benefits of scale and be able to reduce costs. But revenues look more appealing a reason...” Credit Suisse also upgraded Pfizer’s stock status from “Neutral” to “Outperform” based on the merits of the deal. (In fact, Credit Suisse had long recommended a deal between the two.)


Source : IIPM Editorial, 2012.
An Initiative of IIPM, Malay Chaudhuri

For More IIPM Info, Visit below mentioned IIPM articles.

Posted by at
Labels: , , , , , , , , , , , , ,
Subscribe to: Posts (Atom)